Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels

This study aims to investigate the pathophysiology of recurrent pericarditis (RP) by testing for neutralizing autoantibodies against interleukin-1 receptor antagonist (IL-1RA) and measuring soluble urokinase plasminogen activator receptor (suPAR) levels. The hypothesis is that these tests will provide insights into both the inflammatory and non-inflammatory phenotypes of RP, shedding light on the underlying mechanisms. The study will assess the correlation between antibody levels, suPAR levels, and markers of cardiac damage and inflammation. Longitudinal testing during acute episodes and intercritical phases is also planned. The results may guide the use of anakinra, an IL-1 receptor antagonist, in specific clinical scenarios and optimize treatment strategies for RP.

NCT Number	NCT05925790
Lead Sponsor	ASST Fatebenefratelli Sacco Collaborators: Fatebenefratelli Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Ospedale Galeazzi Sant'Ambrogio - IRCCS, Careggi Hospital, Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, Children's Medical Hospital, University of Muenster, Muenster, Germany, University of Homburg, University Hospital Tuebingen
Conditions	Pericarditis
Enrollment	146 participants
Start Date	2023-07-01
Primary Completion	2025-07-01 (estimated)
Study Completion	2025-12-20 (estimated)
Updated on ClinicalTrials.gov	2024-07-03